Allogene Therapeutics Stock Probability of Future Stock Price Finishing Over 7.23

ALLO Stock  USD 4.47  0.01  0.22%   
Allogene Therapeutics' implied volatility is one of the determining factors in the pricing options written on Allogene Therapeutics. Implied volatility approximates the future value of Allogene Therapeutics based on the option's current value. Options with high implied volatility have higher premiums and can be used to hedge the downside of investing in Allogene Therapeutics over a specific time period. For example, 2024-04-19 CALL at $5.0 is a CALL option contract on Allogene Therapeutics' common stock with a strick price of 5.0 expiring on 2024-04-19. The contract was last traded on 2024-03-27 at 15:31:31 for $0.17 and, as of today, has 22 days remaining before the expiration. The option is currently trading at a bid price of $0.1, and an ask price of $0.25. The implied volatility as of the 28th of March is 81.35. View All Allogene options

Closest to current price Allogene long CALL Option Payoff at Expiration

Allogene Therapeutics' future price is the expected price of Allogene Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Allogene Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Allogene Therapeutics Backtesting, Allogene Therapeutics Valuation, Allogene Therapeutics Correlation, Allogene Therapeutics Hype Analysis, Allogene Therapeutics Volatility, Allogene Therapeutics History as well as Allogene Therapeutics Performance.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
  
At this time, Allogene Therapeutics' Price To Sales Ratio is very stable compared to the past year. As of the 28th of March 2024, Price Earnings To Growth Ratio is likely to grow to 0.18, while Price Earnings Ratio is likely to drop (1.62). Please specify Allogene Therapeutics' target price for which you would like Allogene Therapeutics odds to be computed.

Allogene Therapeutics Target Price Odds to finish over 7.23

The tendency of Allogene Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 7.23  or more in 90 days
 4.47 90 days 7.23 
near 1
Based on a normal probability distribution, the odds of Allogene Therapeutics to move over $ 7.23  or more in 90 days from now is near 1 (This Allogene Therapeutics probability density function shows the probability of Allogene Stock to fall within a particular range of prices over 90 days) . Probability of Allogene Therapeutics price to stay between its current price of $ 4.47  and $ 7.23  at the end of the 90-day period is about 31.07 .
Given the investment horizon of 90 days the stock has the beta coefficient of 3.19 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Allogene Therapeutics will likely underperform. Additionally Allogene Therapeutics has an alpha of 0.4554, implying that it can generate a 0.46 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
   Allogene Therapeutics Price Density   
       Price  

Predictive Modules for Allogene Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Allogene Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Allogene Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.234.599.78
Details
Intrinsic
Valuation
LowRealHigh
2.387.5712.76
Details
16 Analysts
Consensus
LowTargetHigh
16.0517.6419.58
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.64-0.41-0.22
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Allogene Therapeutics. Your research has to be compared to or analyzed against Allogene Therapeutics' peers to derive any actionable benefits. When done correctly, Allogene Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Allogene Therapeutics.

Allogene Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Allogene Therapeutics is not an exception. The market had few large corrections towards the Allogene Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Allogene Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Allogene Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
0.46
β
Beta against NYSE Composite3.19
σ
Overall volatility
0.81
Ir
Information ratio 0.14

Allogene Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Allogene Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Allogene Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Allogene Therapeutics is way too risky over 90 days horizon
Allogene Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 95 K. Net Loss for the year was (327.26 M) with profit before overhead, payroll, taxes, and interest of 243 K.
Allogene Therapeutics currently holds about 490.49 M in cash with (237.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41.
Roughly 74.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Acquisition by Arie Belldegrun of 4710121 shares of Allogene Therapeutics subject to Rule 16b-3

Allogene Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Allogene Stock often depends not only on the future outlook of the current and potential Allogene Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Allogene Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding156.9 M
Cash And Short Term Investments448.7 M

Allogene Therapeutics Technical Analysis

Allogene Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Allogene Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Allogene Therapeutics. In general, you should focus on analyzing Allogene Stock price patterns and their correlations with different microeconomic environments and drivers.

Allogene Therapeutics Predictive Forecast Models

Allogene Therapeutics' time-series forecasting models is one of many Allogene Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Allogene Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Allogene Therapeutics

Checking the ongoing alerts about Allogene Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Allogene Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Allogene Therapeutics is way too risky over 90 days horizon
Allogene Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 95 K. Net Loss for the year was (327.26 M) with profit before overhead, payroll, taxes, and interest of 243 K.
Allogene Therapeutics currently holds about 490.49 M in cash with (237.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41.
Roughly 74.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Acquisition by Arie Belldegrun of 4710121 shares of Allogene Therapeutics subject to Rule 16b-3
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:
Check out Allogene Therapeutics Backtesting, Allogene Therapeutics Valuation, Allogene Therapeutics Correlation, Allogene Therapeutics Hype Analysis, Allogene Therapeutics Volatility, Allogene Therapeutics History as well as Allogene Therapeutics Performance.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Allogene Stock analysis

When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.09)
Revenue Per Share
0.001
Quarterly Revenue Growth
(0.55)
Return On Assets
(0.27)
Return On Equity
(0.56)
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.